Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine"
DOI: 10.1007/s12020-020-02359-5
Abstract: Large cardiovascular (CV) outcome trials demonstrated sodium glucose cotransporter 2 inhibitors (SGLT2is) could significantly reduce cardiorenal events in type 2 diabetic adults. However, the effects of SGLT2is on cardiorenal endpoints in many diabetic subpopulations are… read more here.
Keywords: significantly reduce; baseline characteristics; type diabetes; cardiorenal events ... See more keywords